Achilles Therapeutics plc (ACHL)

USD 0.97

(-0.22%)

Market Cap (In USD)

39.66 Million

Revenue (In USD)

-

Net Income (In USD)

-69.66 Million

Avg. Volume

626.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.63-1.76
PE
-
EPS
-
Beta Value
1.344
ISIN
US00449L1026
CUSIP
00449L102
CIK
1830749
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Iraj Ali Ph.D.
Employee Count
-
Website
https://www.achillestx.com
Ipo Date
2021-03-31
Details
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.